Biotech Top Gainer: Ariad Pharmaceuticals (NASDAQ:ARIA), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN), Agenus Inc. (NASDAQ:AGEN)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 8.79% in last session and finished the day at $8.17. Traded volume was 18.32 million shares in the last session and the average volume of the stock remained 16.55 million shares. The beta of the stock remained 1.42. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.

CEL-SCI Corporation (NYSEMKT:CVM) on Mar. 4 announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. CEL-SCI Corporation (NYSEMKT:CVM) rose 20.47% to $1.53 yesterday on volume of 6.15 million shares. The intra-day range of the stock was $1.35 – $1.57. CEL-SCI Corporation (NYSEMKT:CVM) has a market capitalization of 73.77 million.

Synthetic Biologics Inc. (NYSEMKT:SYN) on Mar. 10 announced that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). Synthetic Biologics Inc. (NYSEMKT:SYN)’s stock on March 14, 2014 reported a higher of 6.10% to the closing price of $3.13. Its fifty two weeks range is $0.95 – $3.20. The total market capitalization recorded 139.77 million. The overall volume in the last trading session was 3.62 million shares. In its share capital, Synthetic Biologics Inc. (NYSEMKT:SYN) has 44.65 million outstanding shares.

Agenus Inc. (NASDAQ:AGEN)’s share price rose 7.1% during trading on Friday after MLV & Co. raised their price target on the stock from $9.00 to $11.00, StockRatingsNetwork reports. MLV & Co. currently has a buy rating on the stock. Agenus traded as high as $4.52 and last traded at $4.37, with a volume of 1,140,063 shares traded. The stock had previously closed at $4.08. On Friday, shares of Agenus Inc. (NASDAQ:AGEN) advanced 5.88% to close the day at $4.32. Company return on investment (ROI) is -196.90% and its monthly performance is recorded as 42.57%. Agenus Inc. (NASDAQ:AGEN) quarterly revenue growth is 70.08%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone